ERBB2 and neoplasm: Taking advantage of our PDX model, we were able to show that the novel TIL/neratinib combinatorial strategy, featured by an impressive elevation in the infiltration of GrzB+ T cells in PDX tumor, may be a promising therapeutic alternative for patients with HER2 mutation.